Radiopharm Theranostics Ltd (ASX: RAD) 公布了其放射性药物候选产品Rad101的最新临床数据,该产品在为期六个月的随访中显示出高达86%的初步灵敏度。此项积极结果标志着该疗法在诊断应用领域取得了重要进展。
公司预计,关于Rad101的特异性关键数据将于2026年第四季度对外公布。特异性数据的出炉,将为进一步评估该药物的整体诊断效能提供至关重要的补充信息,从而为未来的临床开发与潜在应用奠定更坚实的基础。
Radiopharm Theranostics Ltd (ASX: RAD) 公布了其放射性药物候选产品Rad101的最新临床数据,该产品在为期六个月的随访中显示出高达86%的初步灵敏度。此项积极结果标志着该疗法在诊断应用领域取得了重要进展。
公司预计,关于Rad101的特异性关键数据将于2026年第四季度对外公布。特异性数据的出炉,将为进一步评估该药物的整体诊断效能提供至关重要的补充信息,从而为未来的临床开发与潜在应用奠定更坚实的基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.